Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization

被引:33
作者
Delpón, E [1 ]
Caballero, R [1 ]
Gómez, R [1 ]
Núñez, L [1 ]
Tamargo, J [1 ]
机构
[1] Univ Complutense, Sch Med, Dept Pharmacol, E-28040 Madrid, Spain
关键词
D O I
10.1016/j.tips.2005.01.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin II and aldosterone produce pro-arrhythmic effects by several mechanisms, including the modulation of voltage-dependent K+ channels involved in human cardiac repolarization. Drugs that inhibit the renin-angiotensin-aidosterone system exert antiarrhythmic actions that are related to the blockade of the pro-arrhythmic actions of angiotensin II and aldosterone. These anti-arrhythmic actions include inhibition of electrical and structural cardiac remodeling, inhibition of neurohumoral activation, reduction of blood pressure and stabilization of electrolyte disturbances. In this article, several angiotensin II AT(1) receptor antagonists (candesartan, E3174, eprosartan, irbesartan and losartan) and aldosterone receptor antagonists (canrenoic acid and spironolactone) that directly modulate the activity of the voltage-dependent K+ channels are reviewed; the effects of these antagonists might be useful in the prevention and treatment of cardiac arrhythmias.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 68 条
[11]   Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels [J].
Caballero, R ;
Moreno, I ;
González, T ;
Arias, C ;
Valenzuela, C ;
Delpón, E ;
Tamargo, J .
CIRCULATION, 2003, 107 (06) :889-895
[12]   Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization [J].
Caballero, R ;
Delpón, E ;
Valenzuela, C ;
Longobardo, M ;
González, T ;
Tamargo, J .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :825-836
[13]   Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents [J].
Caballero, R ;
Delpón, E ;
Valenzuela, C ;
Longobardo, M ;
Tamargo, J .
CIRCULATION, 2000, 101 (10) :1199-1205
[14]   The vascular NAD(P)H oxidases as therapeutic targets cardiovascular diseases [J].
Cai, H ;
Griendling, KK ;
Harrison, DG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (09) :471-478
[15]   Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications [J].
Carey, RM ;
Lin, XH ;
Siragy, HM .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (06) :98S-102S
[16]  
CORABOEUF E, 1974, J PHARMACOL EXP THER, V191, P128
[17]   ANGIOTENSIN-II MODULATES THE DELAYED RECTIFIER POTASSIUM CURRENT OF GUINEA-PIG VENTRICULAR MYOCYTES [J].
DALEAU, P ;
TURGEON, J .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1994, 427 (5-6) :553-555
[18]   Cardiac arrhythmias: the possible role of the renin-angiotensin system [J].
De Mello, WC .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (2-3) :103-108
[19]   The cardiac renin-angiotensin system - Conceptual, or a regulator of cardiac function? [J].
Dostal, DE ;
Baker, KM .
CIRCULATION RESEARCH, 1999, 85 (07) :643-650
[20]   Tissue angiotensin and pathobiology of vascular disease - A unifying hypothesis [J].
Dzau, VJ .
HYPERTENSION, 2001, 37 (04) :1047-1052